One hundred and thirty-nine advanced or metastatic EGFR mutation-positive NSCLC patients with disease progression after first- or second-generation EGFR-TKI therapy were enrolled in this study; all patients underwent first-time re-biopsy by IP methods to identify the T790M mutation (Figure 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.